NMRA CIK: 1885522

Neumora Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY22
FY23
FY24
FY25
FY22 – FY25

Assets

(positive)
Change from FY22 to FY25
billions USD
FY22:
0.39
FY23:
0.48
FY24:
0.31
FY25:
0.19
(positive)
Change from FY22 to FY25
billions USD
FY22:
0.04
FY23:
0.02
FY24:
0.00
FY25:
0.00
Total assets
Change from FY22 to FY25
billions USD
FY22:
0.43
FY23:
0.50
FY24:
0.32
FY25:
0.19

Liabilities & Equity

(negative)
Change from FY22 to FY25
billions USD
FY22:
0.02
FY23:
0.03
FY24:
0.03
FY25:
0.03
(negative)
Change from FY22 to FY25
billions USD
FY22:
0.01
FY23:
0.00
FY24:
0.00
FY25:
0.05
(positive)
Change from FY22 to FY25
billions USD
FY22:
−0.45
FY23:
0.47
FY24:
0.29
FY25:
0.10
Total liabilities & equity
Change from FY23 to FY25
billions USD
FY22:
–
FY23:
0.50
FY24:
0.32
FY25:
0.19

All amounts in billions USD Data source:SEC EDGAR